| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Atherosclerosis | 19 | 2019 | 768 | 4.61 | Why? |
| Cardiovascular Diseases | 27 | 2021 | 11497 | 2.01 | Why? |
| Healthy Lifestyle | 7 | 2020 | 447 | 1.74 | Why? |
| Vascular Calcification | 7 | 2019 | 396 | 1.66 | Why? |
| Gonadal Steroid Hormones | 4 | 2019 | 328 | 1.52 | Why? |
| Vitamin D | 13 | 2019 | 2904 | 1.52 | Why? |
| Postmenopause | 3 | 2019 | 160 | 1.48 | Why? |
| Calcinosis | 5 | 2018 | 240 | 1.42 | Why? |
| Coronary Artery Disease | 11 | 2019 | 2570 | 1.40 | Why? |
| Hypercholesterolemia | 2 | 2019 | 175 | 1.37 | Why? |
| Estradiol | 3 | 2019 | 250 | 1.35 | Why? |
| Testosterone | 4 | 2019 | 596 | 1.17 | Why? |
| Aortic Valve | 4 | 2019 | 664 | 1.15 | Why? |
| Primary Prevention | 4 | 2020 | 778 | 1.12 | Why? |
| Mitral Valve | 2 | 2018 | 342 | 1.07 | Why? |
| Dehydroepiandrosterone | 3 | 2019 | 14 | 1.06 | Why? |
| Sex Hormone-Binding Globulin | 3 | 2019 | 57 | 1.06 | Why? |
| Minerals | 3 | 2018 | 86 | 1.03 | Why? |
| Apolipoproteins B | 2 | 2019 | 47 | 1.00 | Why? |
| Vitamins | 5 | 2018 | 1208 | 0.98 | Why? |
| Aortic Valve Stenosis | 3 | 2019 | 741 | 0.92 | Why? |
| Risk Reduction Behavior | 6 | 2019 | 946 | 0.90 | Why? |
| Dietary Supplements | 7 | 2021 | 2251 | 0.89 | Why? |
| Parathyroid Hormone | 3 | 2018 | 98 | 0.89 | Why? |
| Peripheral Arterial Disease | 4 | 2019 | 471 | 0.85 | Why? |
| Metabolic Syndrome | 2 | 2019 | 810 | 0.84 | Why? |
| Anticholesteremic Agents | 2 | 2019 | 186 | 0.83 | Why? |
| Health Status | 6 | 2019 | 3259 | 0.74 | Why? |
| Fibroblast Growth Factors | 5 | 2019 | 119 | 0.72 | Why? |
| Calcium | 4 | 2018 | 708 | 0.72 | Why? |
| Heart Rate | 2 | 2018 | 1527 | 0.72 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2019 | 1510 | 0.72 | Why? |
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2018 | 36 | 0.71 | Why? |
| Coronary Vessels | 5 | 2018 | 914 | 0.71 | Why? |
| Acute-Phase Proteins | 1 | 2018 | 177 | 0.68 | Why? |
| Secondary Prevention | 2 | 2020 | 762 | 0.68 | Why? |
| Hypolipidemic Agents | 1 | 2019 | 208 | 0.67 | Why? |
| Polycystic Ovary Syndrome | 1 | 2019 | 151 | 0.66 | Why? |
| Physicians, Women | 1 | 2020 | 221 | 0.64 | Why? |
| Sexism | 1 | 2020 | 278 | 0.64 | Why? |
| Dyslipidemias | 3 | 2019 | 791 | 0.63 | Why? |
| Cognitive Dysfunction | 2 | 2018 | 1389 | 0.62 | Why? |
| Return to Sport | 1 | 2021 | 456 | 0.60 | Why? |
| Cardiologists | 1 | 2020 | 366 | 0.59 | Why? |
| Health Status Indicators | 1 | 2018 | 341 | 0.57 | Why? |
| Cholecalciferol | 1 | 2018 | 246 | 0.57 | Why? |
| Vitamin D Deficiency | 5 | 2017 | 1782 | 0.57 | Why? |
| Smokers | 1 | 2020 | 550 | 0.56 | Why? |
| Coronary Angiography | 4 | 2019 | 2275 | 0.55 | Why? |
| Cholesterol, LDL | 4 | 2019 | 499 | 0.55 | Why? |
| Lipids | 3 | 2019 | 1079 | 0.55 | Why? |
| Coronary Stenosis | 1 | 2018 | 273 | 0.54 | Why? |
| Computed Tomography Angiography | 4 | 2018 | 2153 | 0.54 | Why? |
| Biomarkers | 18 | 2019 | 23361 | 0.53 | Why? |
| Accidental Falls | 1 | 2018 | 448 | 0.52 | Why? |
| Preventive Health Services | 1 | 2019 | 501 | 0.52 | Why? |
| Heart Valve Diseases | 1 | 2017 | 355 | 0.51 | Why? |
| Plaque, Atherosclerotic | 4 | 2019 | 423 | 0.51 | Why? |
| Risk Assessment | 20 | 2019 | 25439 | 0.50 | Why? |
| C-Reactive Protein | 3 | 2018 | 7972 | 0.49 | Why? |
| Sarcopenia | 1 | 2018 | 422 | 0.48 | Why? |
| Natriuretic Peptide, Brain | 1 | 2018 | 1215 | 0.44 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2017 | 533 | 0.43 | Why? |
| Muscle, Skeletal | 1 | 2018 | 915 | 0.43 | Why? |
| Exercise Test | 1 | 2017 | 911 | 0.42 | Why? |
| Risk Factors | 35 | 2021 | 71621 | 0.42 | Why? |
| Transcatheter Aortic Valve Replacement | 1 | 2019 | 839 | 0.41 | Why? |
| Smoking | 5 | 2020 | 3358 | 0.40 | Why? |
| Cognition | 1 | 2018 | 1394 | 0.38 | Why? |
| Exercise | 8 | 2019 | 6771 | 0.37 | Why? |
| Cardiology | 2 | 2021 | 2873 | 0.37 | Why? |
| Endothelium, Vascular | 2 | 2019 | 1751 | 0.36 | Why? |
| Incidence | 20 | 2020 | 25622 | 0.36 | Why? |
| Personal Satisfaction | 1 | 2018 | 1243 | 0.36 | Why? |
| Proportional Hazards Models | 10 | 2019 | 6543 | 0.35 | Why? |
| Peptide Fragments | 1 | 2018 | 2075 | 0.35 | Why? |
| Aorta, Thoracic | 3 | 2018 | 271 | 0.33 | Why? |
| Prospective Studies | 17 | 2019 | 43301 | 0.33 | Why? |
| Inflammation Mediators | 1 | 2018 | 2654 | 0.33 | Why? |
| Female | 62 | 2021 | 380317 | 0.33 | Why? |
| Inflammation | 4 | 2021 | 13255 | 0.33 | Why? |
| Environmental Exposure | 1 | 2017 | 1558 | 0.33 | Why? |
| Middle Aged | 50 | 2020 | 270681 | 0.33 | Why? |
| Aged | 43 | 2020 | 215776 | 0.33 | Why? |
| Cholesterol | 4 | 2018 | 660 | 0.32 | Why? |
| Alcohol Drinking | 1 | 2018 | 1663 | 0.32 | Why? |
| Male | 56 | 2021 | 367725 | 0.31 | Why? |
| Cross-Sectional Studies | 16 | 2019 | 53120 | 0.31 | Why? |
| Humans | 86 | 2021 | 930598 | 0.31 | Why? |
| Frailty | 1 | 2017 | 1432 | 0.29 | Why? |
| Particulate Matter | 1 | 2017 | 3249 | 0.29 | Why? |
| Prognosis | 12 | 2021 | 32490 | 0.27 | Why? |
| Adiposity | 2 | 2017 | 329 | 0.26 | Why? |
| Heart Injuries | 2 | 2020 | 608 | 0.26 | Why? |
| Follow-Up Studies | 7 | 2018 | 17020 | 0.26 | Why? |
| United States | 21 | 2019 | 46150 | 0.26 | Why? |
| Adenosine Monophosphate | 1 | 2021 | 5652 | 0.25 | Why? |
| Alanine | 1 | 2021 | 5687 | 0.25 | Why? |
| Neuropsychological Tests | 2 | 2018 | 954 | 0.24 | Why? |
| Blood Pressure | 6 | 2018 | 2198 | 0.24 | Why? |
| Longitudinal Studies | 7 | 2019 | 9893 | 0.23 | Why? |
| Antibodies, Monoclonal | 2 | 2018 | 8041 | 0.23 | Why? |
| Aged, 80 and over | 25 | 2019 | 88759 | 0.22 | Why? |
| Coronary Disease | 2 | 2017 | 645 | 0.22 | Why? |
| Myocardial Infarction | 1 | 2017 | 3361 | 0.22 | Why? |
| Sex Distribution | 2 | 2018 | 2083 | 0.21 | Why? |
| Mortality | 1 | 2017 | 7132 | 0.21 | Why? |
| Dicarboxylic Acids | 1 | 2019 | 12 | 0.20 | Why? |
| Sex Factors | 6 | 2021 | 11014 | 0.20 | Why? |
| Avitaminosis | 1 | 2019 | 20 | 0.20 | Why? |
| Air Pollutants | 1 | 2017 | 3110 | 0.20 | Why? |
| Ankle Brachial Index | 1 | 2019 | 53 | 0.20 | Why? |
| Ezetimibe | 1 | 2019 | 50 | 0.20 | Why? |
| RGS Proteins | 1 | 2018 | 5 | 0.20 | Why? |
| Atrial Fibrillation | 3 | 2019 | 2320 | 0.19 | Why? |
| Vitamin D3 24-Hydroxylase | 1 | 2018 | 13 | 0.19 | Why? |
| Fruit | 2 | 2019 | 313 | 0.19 | Why? |
| Abdominal Muscles | 1 | 2018 | 26 | 0.19 | Why? |
| Apolipoproteins C | 1 | 2018 | 3 | 0.19 | Why? |
| Air Pollution | 1 | 2017 | 3504 | 0.19 | Why? |
| Dietary Approaches To Stop Hypertension | 1 | 2018 | 8 | 0.19 | Why? |
| Vegetables | 2 | 2019 | 340 | 0.19 | Why? |
| Women's Health | 2 | 2019 | 444 | 0.19 | Why? |
| Calcium, Dietary | 1 | 2018 | 21 | 0.19 | Why? |
| Stroke Volume | 2 | 2019 | 2153 | 0.18 | Why? |
| Brachial Artery | 1 | 2019 | 107 | 0.18 | Why? |
| American Heart Association | 2 | 2017 | 347 | 0.18 | Why? |
| Blood Glucose | 5 | 2018 | 3642 | 0.18 | Why? |
| Thigh | 1 | 2018 | 55 | 0.18 | Why? |
| Maryland | 2 | 2017 | 436 | 0.18 | Why? |
| Women's Health Services | 1 | 2019 | 51 | 0.18 | Why? |
| Actigraphy | 1 | 2018 | 102 | 0.18 | Why? |
| Florida | 2 | 2018 | 598 | 0.18 | Why? |
| Nitrogen Oxides | 1 | 2017 | 72 | 0.18 | Why? |
| Electrophoresis | 1 | 2017 | 35 | 0.18 | Why? |
| Multivariate Analysis | 3 | 2018 | 5440 | 0.18 | Why? |
| Phosphorus | 1 | 2018 | 80 | 0.18 | Why? |
| Authorship | 1 | 2021 | 240 | 0.18 | Why? |
| Calcitriol | 1 | 2018 | 84 | 0.17 | Why? |
| Troponin | 2 | 2021 | 1058 | 0.17 | Why? |
| Fatty Acids | 1 | 2019 | 238 | 0.17 | Why? |
| Chi-Square Distribution | 2 | 2018 | 961 | 0.17 | Why? |
| Mississippi | 1 | 2017 | 80 | 0.17 | Why? |
| Body Composition | 2 | 2018 | 414 | 0.17 | Why? |
| Incidental Findings | 2 | 2019 | 487 | 0.17 | Why? |
| Predictive Value of Tests | 5 | 2019 | 9537 | 0.17 | Why? |
| Body Height | 1 | 2017 | 100 | 0.17 | Why? |
| Polysomnography | 1 | 2018 | 296 | 0.16 | Why? |
| Heart Failure | 4 | 2019 | 6638 | 0.16 | Why? |
| Vitamin D-Binding Protein | 1 | 2017 | 83 | 0.16 | Why? |
| Vasodilation | 1 | 2019 | 258 | 0.16 | Why? |
| Depression | 2 | 2019 | 14116 | 0.16 | Why? |
| Lipoprotein(a) | 1 | 2017 | 92 | 0.16 | Why? |
| Arteries | 1 | 2019 | 283 | 0.16 | Why? |
| Breast | 1 | 2019 | 290 | 0.16 | Why? |
| Androgens | 1 | 2019 | 267 | 0.16 | Why? |
| Treatment Outcome | 9 | 2021 | 51732 | 0.16 | Why? |
| Asian Americans | 2 | 2018 | 387 | 0.16 | Why? |
| Cohort Studies | 10 | 2018 | 36005 | 0.16 | Why? |
| Vascular Stiffness | 1 | 2019 | 264 | 0.15 | Why? |
| Physical Fitness | 1 | 2019 | 334 | 0.15 | Why? |
| Smoking Cessation | 3 | 2018 | 826 | 0.15 | Why? |
| Meditation | 1 | 2017 | 140 | 0.15 | Why? |
| Bone and Bones | 1 | 2017 | 235 | 0.15 | Why? |
| Protein Processing, Post-Translational | 1 | 2018 | 634 | 0.15 | Why? |
| Minnesota | 1 | 2017 | 509 | 0.14 | Why? |
| Drug Costs | 1 | 2019 | 313 | 0.14 | Why? |
| HIV Infections | 2 | 2018 | 11620 | 0.14 | Why? |
| Body Mass Index | 5 | 2018 | 4306 | 0.14 | Why? |
| Eligibility Determination | 1 | 2017 | 255 | 0.14 | Why? |
| Pregnancy Complications, Cardiovascular | 1 | 2018 | 231 | 0.14 | Why? |
| Muscle Strength | 1 | 2017 | 317 | 0.14 | Why? |
| Mammography | 1 | 2019 | 410 | 0.14 | Why? |
| Serine Proteinase Inhibitors | 1 | 2019 | 341 | 0.14 | Why? |
| Tomography, X-Ray Computed | 3 | 2018 | 25144 | 0.14 | Why? |
| Lipid Metabolism | 1 | 2019 | 572 | 0.14 | Why? |
| Time Factors | 10 | 2019 | 31397 | 0.14 | Why? |
| African Americans | 4 | 2018 | 3363 | 0.14 | Why? |
| Ascorbic Acid | 1 | 2021 | 676 | 0.14 | Why? |
| North Carolina | 1 | 2017 | 571 | 0.14 | Why? |
| Glycosylation | 1 | 2018 | 1255 | 0.14 | Why? |
| Stress, Psychological | 1 | 2018 | 10231 | 0.14 | Why? |
| Amino Acids | 1 | 2018 | 552 | 0.13 | Why? |
| Muscle Weakness | 1 | 2017 | 406 | 0.13 | Why? |
| Carotid Artery Diseases | 1 | 2017 | 251 | 0.13 | Why? |
| Aortic Diseases | 1 | 2018 | 362 | 0.13 | Why? |
| Zinc | 1 | 2021 | 817 | 0.13 | Why? |
| Bibliometrics | 1 | 2021 | 731 | 0.12 | Why? |
| Angiotensin Receptor Antagonists | 2 | 2020 | 3892 | 0.12 | Why? |
| Pre-Eclampsia | 1 | 2019 | 599 | 0.12 | Why? |
| Athletes | 1 | 2021 | 1047 | 0.12 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2021 | 10649 | 0.12 | Why? |
| Anxiety | 1 | 2018 | 17311 | 0.11 | Why? |
| Survival Rate | 4 | 2020 | 9206 | 0.11 | Why? |
| Health Expenditures | 1 | 2019 | 904 | 0.11 | Why? |
| Weight Loss | 1 | 2017 | 826 | 0.11 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2020 | 5277 | 0.11 | Why? |
| Hemodynamics | 1 | 2019 | 1562 | 0.11 | Why? |
| Clinical Decision-Making | 3 | 2019 | 3755 | 0.11 | Why? |
| Educational Status | 1 | 2017 | 1451 | 0.11 | Why? |
| Linear Models | 1 | 2017 | 1914 | 0.11 | Why? |
| Cardiovascular System | 1 | 2018 | 750 | 0.10 | Why? |
| Prevalence | 5 | 2020 | 25773 | 0.10 | Why? |
| Ventricular Function, Left | 1 | 2019 | 1555 | 0.10 | Why? |
| Coinfection | 2 | 2020 | 6820 | 0.09 | Why? |
| Odds Ratio | 2 | 2018 | 5861 | 0.09 | Why? |
| Recovery of Function | 1 | 2019 | 2461 | 0.09 | Why? |
| Bayes Theorem | 1 | 2018 | 3237 | 0.09 | Why? |
| Myocardium | 1 | 2020 | 2323 | 0.09 | Why? |
| Drug Combinations | 1 | 2018 | 3852 | 0.09 | Why? |
| Age Distribution | 1 | 2018 | 3567 | 0.09 | Why? |
| Protective Factors | 3 | 2019 | 1720 | 0.09 | Why? |
| Periodicals as Topic | 1 | 2021 | 1492 | 0.09 | Why? |
| Patient Selection | 2 | 2019 | 4560 | 0.09 | Why? |
| Glomerular Filtration Rate | 3 | 2019 | 1262 | 0.09 | Why? |
| Aging | 2 | 2018 | 3581 | 0.08 | Why? |
| Double-Blind Method | 1 | 2018 | 5988 | 0.08 | Why? |
| Frail Elderly | 1 | 2016 | 1427 | 0.08 | Why? |
| Renin-Angiotensin System | 2 | 2020 | 3661 | 0.08 | Why? |
| Diet | 1 | 2019 | 2052 | 0.08 | Why? |
| Antihypertensive Agents | 1 | 2019 | 1962 | 0.08 | Why? |
| Nutrition Surveys | 2 | 2018 | 287 | 0.08 | Why? |
| Kidney | 2 | 2018 | 3648 | 0.08 | Why? |
| Hepatitis C | 1 | 2017 | 1514 | 0.08 | Why? |
| Residence Characteristics | 1 | 2017 | 1927 | 0.08 | Why? |
| Premature Birth | 1 | 2018 | 2151 | 0.08 | Why? |
| Health Promotion | 1 | 2019 | 2020 | 0.07 | Why? |
| Sleep | 1 | 2018 | 2695 | 0.07 | Why? |
| Uncertainty | 1 | 2017 | 1888 | 0.07 | Why? |
| Feeding Behavior | 1 | 2018 | 1909 | 0.07 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.07 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.07 | Why? |
| Decision Making | 1 | 2019 | 3132 | 0.07 | Why? |
| Life Style | 1 | 2018 | 2708 | 0.07 | Why? |
| Asymptomatic Diseases | 1 | 2017 | 3444 | 0.07 | Why? |
| Pregnancy Outcome | 1 | 2018 | 3803 | 0.07 | Why? |
| Magnetic Resonance Imaging | 1 | 2021 | 6551 | 0.07 | Why? |
| Kaplan-Meier Estimate | 3 | 2018 | 4260 | 0.07 | Why? |
| Disease Progression | 3 | 2018 | 13580 | 0.07 | Why? |
| Retrospective Studies | 6 | 2021 | 105322 | 0.06 | Why? |
| Age Factors | 3 | 2018 | 21039 | 0.06 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.06 | Why? |
| Immunoassay | 1 | 2017 | 4485 | 0.06 | Why? |
| Postoperative Complications | 1 | 2019 | 5861 | 0.05 | Why? |
| Cause of Death | 3 | 2019 | 4823 | 0.05 | Why? |
| Registries | 1 | 2020 | 12327 | 0.05 | Why? |
| Severity of Illness Index | 4 | 2021 | 48226 | 0.05 | Why? |
| Socioeconomic Factors | 1 | 2018 | 8495 | 0.05 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.05 | Why? |
| Nuts | 1 | 2019 | 22 | 0.05 | Why? |
| Hypertension | 2 | 2019 | 8895 | 0.05 | Why? |
| Edible Grain | 1 | 2019 | 26 | 0.05 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.05 | Why? |
| Sodium-Phosphate Cotransporter Proteins, Type IIa | 1 | 2018 | 2 | 0.05 | Why? |
| Adult | 12 | 2020 | 244371 | 0.05 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.05 | Why? |
| Health Status Disparities | 1 | 2017 | 4072 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2018 | 9335 | 0.05 | Why? |
| Fishes | 1 | 2019 | 99 | 0.05 | Why? |
| Aortography | 1 | 2018 | 60 | 0.05 | Why? |
| Ideal Body Weight | 1 | 2017 | 18 | 0.04 | Why? |
| Phosphates | 1 | 2018 | 135 | 0.04 | Why? |
| Ultracentrifugation | 1 | 2017 | 63 | 0.04 | Why? |
| Practice Guidelines as Topic | 2 | 2019 | 15421 | 0.04 | Why? |
| Recommended Dietary Allowances | 1 | 2017 | 43 | 0.04 | Why? |
| Veterans Health | 1 | 2019 | 169 | 0.04 | Why? |
| Proprotein Convertase 9 | 1 | 2019 | 141 | 0.04 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2018 | 6166 | 0.04 | Why? |
| Carotid Artery, Common | 1 | 2017 | 49 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.04 | Why? |
| Multimodal Imaging | 1 | 2021 | 534 | 0.04 | Why? |
| Surveys and Questionnaires | 3 | 2019 | 43792 | 0.04 | Why? |
| Protein Isoforms | 1 | 2017 | 347 | 0.04 | Why? |
| Carotid Artery, Internal | 1 | 2017 | 97 | 0.04 | Why? |
| Young Adult | 4 | 2019 | 93724 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Meat | 1 | 2019 | 380 | 0.04 | Why? |
| Biological Availability | 1 | 2017 | 388 | 0.04 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.04 | Why? |
| Models, Economic | 1 | 2019 | 316 | 0.04 | Why? |
| Disease-Free Survival | 1 | 2020 | 1654 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 8811 | 0.03 | Why? |
| Triglycerides | 1 | 2017 | 478 | 0.03 | Why? |
| Hyperlipidemias | 1 | 2016 | 290 | 0.03 | Why? |
| Magnetic Resonance Imaging, Cine | 1 | 2018 | 669 | 0.03 | Why? |
| Texas | 1 | 2019 | 1237 | 0.03 | Why? |
| Patient Reported Outcome Measures | 1 | 2019 | 912 | 0.03 | Why? |
| United States Department of Veterans Affairs | 1 | 2017 | 553 | 0.03 | Why? |
| Hematologic Tests | 1 | 2017 | 521 | 0.03 | Why? |
| Costs and Cost Analysis | 1 | 2017 | 694 | 0.03 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.03 | Why? |
| Evidence-Based Practice | 1 | 2018 | 693 | 0.03 | Why? |
| Insulin Resistance | 1 | 2017 | 669 | 0.03 | Why? |
| Regression Analysis | 1 | 2019 | 2484 | 0.03 | Why? |
| Mass Spectrometry | 1 | 2017 | 1165 | 0.03 | Why? |
| Decision Support Techniques | 1 | 2019 | 903 | 0.03 | Why? |
| Genome-Wide Association Study | 1 | 2018 | 1648 | 0.03 | Why? |
| Heart | 1 | 2021 | 1791 | 0.03 | Why? |
| Up-Regulation | 1 | 2019 | 2249 | 0.03 | Why? |
| Glycated Hemoglobin A | 1 | 2018 | 1316 | 0.03 | Why? |
| Sleep Apnea, Obstructive | 1 | 2018 | 668 | 0.03 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.03 | Why? |
| Hospitalization | 2 | 2019 | 54280 | 0.03 | Why? |
| Cerebrovascular Disorders | 1 | 2018 | 1040 | 0.02 | Why? |
| Case-Control Studies | 2 | 2019 | 17671 | 0.02 | Why? |
| Limit of Detection | 1 | 2017 | 2698 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2019 | 2259 | 0.02 | Why? |
| Antimalarials | 1 | 2020 | 2505 | 0.02 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.02 | Why? |
| Veterans | 1 | 2018 | 1131 | 0.02 | Why? |
| Sleep Initiation and Maintenance Disorders | 1 | 2018 | 1692 | 0.02 | Why? |
| Pregnancy | 2 | 2019 | 23879 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2019 | 3228 | 0.02 | Why? |
| Risk | 1 | 2018 | 5288 | 0.02 | Why? |
| Global Health | 2 | 2020 | 13911 | 0.02 | Why? |
| Guideline Adherence | 1 | 2018 | 2309 | 0.02 | Why? |
| Electrocardiography | 1 | 2019 | 3957 | 0.02 | Why? |
| Renal Insufficiency, Chronic | 1 | 2017 | 2654 | 0.01 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2019 | 11304 | 0.01 | Why? |
| Databases, Factual | 1 | 2017 | 6248 | 0.01 | Why? |
| Ultrasonography | 1 | 2017 | 4409 | 0.01 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2019 | 7330 | 0.01 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.01 | Why? |
| Quality of Life | 1 | 2019 | 9820 | 0.01 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.01 | Why? |
| Infant, Newborn | 1 | 2018 | 23105 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Diabetes Mellitus | 1 | 2016 | 8207 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| Animals | 1 | 2019 | 78931 | 0.01 | Why? |
| Adolescent | 1 | 2019 | 86841 | 0.01 | Why? |